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Background: We describe our experiences with vaginal vault resection for vaginal recurrence of cervical cancer
after hysterectomy and radiotherapy. After operative treatment, the rate of vaginal vault recurrence of uterine
cervical cancer is reported to be about 5%. There is no consensus regarding the treatment for these cases.
Methods: Between 2004 and 2012, eight patients with vaginal vault recurrence underwent removal of the vaginal
wall via laparotomy after hysterectomy and radiotherapy.
Results: The median patient age was 45 years (range 35 to 70 years). The median operation time was 244.5 min
(range 172 to 590 min), the median estimated blood loss was 362.5 mL (range 49 to 1,890 mL), and the median
duration of hospitalization was 24.5 days (range 11 to 50 days). Two patients had intraoperative complications: a
grade 1 bowel injury and a grade 1 bladder injury. The following postoperative complications were observed: one
patient had vaginal vault bleeding, three patients developed vesicovaginal fistulae, and one patient had repeated
ileus. Two patients needed clean intermittent catheterization. Local control was achieved in five of the eight cases.
Conclusions: Vaginal vault resection is an effective treatment for vaginal recurrence of cervical cancer after
hysterectomy and radiotherapy. However, complications of this procedure can be expected to reduce quality of life.
Therefore, this operation should be selected with great care.
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Cervical cancer is the fourth most common cancer in
women worldwide. In 2012, 528,000 cases of cervical
cancer were diagnosed globally and 266,000 deaths were
attributed to this disease [1]. In Japan, the incidence of
early stage cervical cancer is increasing among younger
women [2]. There are many long-term survivors of these
cancers, and those who experience locoregional recur-
rence after initial surgery may require radiotherapy [3].
In most cases, radiotherapy can control vaginal vault re-
currence [4,5], but additional relapse is occasionally ex-
perienced. If it is feasible, surgical resection is generally
considered for such cases. Vaginal vault resection is a
technique that is applicable to rare clinical cases. Only a* Correspondence: akiko06090111@yahoo.co.jp
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unless otherwise stated.few reports have described the efficacy of laparoscopic
or vaginal vaginectomy [6,7]. To the best of our know-
ledge, this is the first study to report on vault resection
performed via laparotomy. In the present study, we
aimed to describe the efficacy and feasibility of vaginal
vault resection by laparotomy for isolated small vaginal
relapse of cervical cancer.Methods
Eight patients were evaluated, each of whom experienced
isolated vaginal relapse of uterine cervical cancer, and each
of whom subsequently underwent vaginal vault resection
by laparotomy at Cancer Institute Hospital (Tokyo, Japan)
between 2004 and 2012. This research was performed with
the approval of the Regional Ethics Committee for Clinical
Study of the Cancer Institute Hospital, Tokyo, Japan, and
in compliance with the Helsinki Declaration. The medicalis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The vaginal apex identified using Hegar sounds and
pulled via the apex (A) and pelvic appearance after
vaginectomy (B).
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Table 1 shows the patients’ characteristics. Four patients
were referred to our institute after prior hysterectomy,
and four patients had undergone hysterectomy at our hos-
pital. Hysterectomy was performed as simple extrafascial
abdominal hysterectomy (four patients), vaginal hysterec-
tomy (one patient), modified hysterectomy (two patients),
or radical hysterectomy (one patient). In four patients,
hysterectomy was combined with bilateral salpingo-
oophorectomy, and in three patients, it was combined
with pelvic lymphadenectomy.
Some patients had been treated with radiation using re-
mote afterloading systems for positive margins of hyster-
ectomy, and other patients had been treated for first
vaginal vault recurrence after hysterectomy. After brachy-
therapy, some patients developed vaginal vault recurrence.
Recurrences were treated with vaginal vault resection by
laparotomy in eight cases. The intervals between brachy-
therapy and vaginal vault recurrences varied from 9 to
44 months. The patients were asked to indicate that they
understood the nature of the surgical procedure, operative
complications, and postoperative complications.
Surgical procedures were performed as follows (Figures 1
and 2). After bringing the patient into the Trendelenburg
position, bilateral ureteral catheters and a Foley catheter
were inserted under general anesthesia. Laparotomy was
then performed, and exploration of the abdomen did not
reveal other lesions in any of the cases. Adhesiolysis was
performed between the rectum and the scar from the pre-
vious surgery. The pararectal and paravesical spaces were
developed, and the surface of the levator ani muscle was
exposed. Division between the posterior vaginal wall and
the rectum was performed close to the muscular layer of
the rectum, and this dissection plane was continued to the
perineal body. The vaginal apex was identified using Hegar
sounds and pulled via the apex. Ventral to the vagina, the
plane of excision was placed in line with the limit of the
muscular layer of the bladder. Subsequently, we resected
the parametrium lateral to the vagina with the intention ofTable 1 Clinical features of the patients at the initial operatio
Case 1 Case 2 Case 3
Age 69 35 43
Initial stage 0 0 0
Histology AS in situ CIS AIS
Initial operation TAH TAH MRH + BSO + PLA
Vaginal margin Negative Positive Negative
Adaptation of radiation
treatment
Adjuvant Recurrence Recurrence
Interval between initial
operation and vaginectomy
12 M 13 M 44 M
AS, adenosquamous cell carcinoma; CIS, carcinoma in situ; AIS, adenocarcinoma in s
hysterectomy; MRH, modified radical hysterectomy; BSO, bilateral salpingo-oophore
total hysterectomy; NA, not available.preserving the nerve branches running from the inferior
hypogastric plexus into the bladder. The vaginal wall was
exfoliated via the transvaginal approach, and the vaginal
vault was totally removed. Subsequently, the dissected end
of the levator ani muscle was closed with sutures. We did
not close the perineal opening, which was the dissecting
line of the lower edge of the vagina. Finally, the bladder
was filled with saline to check for leakage.Results
Patient characteristics at the initial operation are sum-
marized in Table 1. The median patient age was 45 years
(range 35 to 70 years), the median body mass index was
19.7 (range 16.8 to 24.5), and all patients met the criteria
for American Society of Anesthesiologists physical status
(PS) classification 1 to 2. Three patients were diagnosed
with carcinoma in situ: one patient was diagnosed with
carcinoma in situ, one patient was diagnosed with ade-
nosquamous cell carcinoma in situ, and one patient was
diagnosed with adenocarcinoma in situ. Three patients
had stage Ia disease: two had squamous cell carcinoma,
and one had adenocarcinoma. Two patients had stage II
disease: one had squamous cell carcinoma and one had
adenosquamous cell carcinoma. Vaginal surgical marginsn
Case 4 Case 5 Case 6 Case 7 Case 8
41 33 30 44 49
Ia Ia Ia IIa IIb
SCC AC SCC SCC AS
TAH RH + BSO + PLA VTH MRH + BSO RH + BSO + PLA
NA Negative Positive Positive NA
Adjuvant Recurrence Recurrence Adjuvant Recurrence
12 M 9 M 38 M 12 M 10 M
itu; SCC, squamous cell carcinoma; AC, adenocarcinoma; TAH, total abdominal
ctomy; PLA, pelvic lymphadenectomy; RH, radical hysterectomy; VTH, vaginal
Figure 2 The vaginal appearance after the operation (A) and
the dissected vaginal specimen (B).
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unavailable in two cases.
Table 2 presents operative data regarding resection of
the vaginal vault and complications. The surgical margins
were positive in four cases, negative in three cases, and
unclear in one case, as caused by coagulation. The median
operation time was 244.5 min (range 172 to 590 min), and
the median estimated blood loss was 362.5 mL (range 49
to 1,890 mL). Bilateral ureteral catheters were inserted in
seven patients. The Foley catheter was removed after a
median of 7 days (range 3 to 20 days). Two patients
needed clean intermittent catheterization after removal of
the Foley catheter. The median hospital stay was 24.5 days
(range 11 to 50 days).
With regard to postoperative complications, one pa-
tient experienced vaginal vault bleeding. Another patient
experienced repeated ileus. Three patients developed
vesicovaginal fistulae (Figure 3). For each of these pa-
tients, the Foley catheter was kept in place for 3 months,
after which the fistula spontaneously closed. The median
follow-up period after the resection of vault failure was
44.5 months (range 22 to 76 months). Regarding post-
treatment surveillance, physical examinations were per-
formed, with cytological investigation of the vaginal
vault and transvaginal ultrasound (every 2 months for
2 years and every 4 months for another 3 years there-
after). After vaginal vault resection, three patients were
disease-free and had good general condition. Five other
patients developed recurrence: two developed distant
metastasis, two developed locoregional failure, and one
developed locoregional and distant metastasis. The me-
dian time to recurrence after vaginal resection was
10 months (range 2 to 22 months).
Two patients showed lymph node involvement after
treatment for relapse. One of these patients had pelvic
lymph node metastasis and was treated with radiotherapy.
The other had para-aortic lymph node metastasis and was
treated with chemotherapy. At the last follow-up, both
patients were alive and well, with no evidence of disease.
A patient with locoregional failure showed recurrence inthe vagina, and pelvic exenteration and ureteroileostomy
were performed. This patient died due to peritoneal dis-
semination 23 months after vaginal resection. A patient
with locoregional and distant failure showed recurrence in
the vulva after vaginal vault resection. The tumor was par-
tially resected from the vulva. Furthermore, this patient
developed multiple liver metastases 30 months later. With
respect to postoperative complications, repeated ileus was
managed with some difficulty. After a symptom was im-
proved by fasting, this patient was treated with TS-1,
resulting in the shrinkage of the recurrent tumors, and
proton beam therapy was performed. Forty-five months
after vaginal vault resection, the patient was alive with dis-
ease at the last follow-up.
Discussion
The rate of vaginal vault recurrence of stages I to II
uterine cervical cancer after operative treatment has
been reported to be 4.9% [8]. No consensus has been
reached regarding the selection of multimodal treatment
strategies. In general, radiotherapy is effective in terms
of local control with vaginal vault recurrence. We treated
first vaginal relapse with radiotherapy, and although 95%
patients were cured at our hospital, we sometimes ob-
served second vaginal failures after providing radiotherapy
for first vaginal relapse.
In a prior study, Berek et al. noted that intent-to-cure
recurrent cervical carcinoma was the indication for pelvic
exenteration after prior pelvic radiotherapy [9]. Although
they found pelvic exenteration to be a feasible surgical
procedure, it was associated with severe complications.
Accordingly, Berek et al. described using pelvic exenter-
ation as a last option for surgical therapy.
Panici et al. reported that the complications of pelvic
exenteration include the development of ileus in 42% of
patients (5/12), the requirement of re-laparotomy in 17%
of patients (2/12), and the occurrence of leaks after in-
testinal anastomosis in 37.5% of patients (3/8) [7]. Panici
et al.’s report further showed that the median operative
time was 491.5 min, the estimated blood loss was
2537.5 mL, and the median hospital stay was 65.5 days.
Another report has also shown similar results, including
major and minor complication rates of 34% and 57%, re-
spectively [10]. Complete resection with exenteration is
a significant prognostic factor for local control and sur-
vival, but it is also associated with high morbidity.
We have treated first vaginal relapse with radiotherapy
and performed surgery for second vaginal failures. In
consideration of morbidity, we have used surgery for re-
section of the vaginal vault, instead of using pelvic exen-
teration. The indication of resection for vault failure
after hysterectomy and radiation included the following:
1) superficially carcinoma, 2) an interval of greater than
6 months between the initial operation and vault failure,
Table 2 Clinical feature of the patients at vaginectomy
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8
Age 70 36 48 44 35 36 46 54
Operative time (min), for vaginectomy 180 590 219 172 270 316 191 442
Blood loss, mL 250 1,890 49 150 365 490 360 760
Intraoperative complications Rectal injury G1 None Bladder injury G1 None None None None None
Postoperative complications Cystitis Vesicovaginal fistula
(POD33)
Vesicovaginal fistula
(POD40), ileus, nephritis
None None Nephritis Vesicovaginal fistula
(POD19), nephritis
Stump bleeding
Self-catheterization No No No No + No No +
Margin of resection Positive Positive Unclear Positive Negative Positive Negative Negative
Site of recurrence after colpectomy PLN Pelvic wall Vulva No No PAN No Vulva PLN
Treatment for recurrence after colpectomy Radiation Exenteration Vulvectomy Chemotherapy Vulvectomy +
lymphadenectomy
Time to recurrence from colpectomy 10 M 2 M 6 M 22 M 19 M
Final status AWD DOD AWD NED NED AWD NED AWD
POD, postoperative day; PLN, pelvic lymph node; PAN, para-aortic lymph node; AWD, alive with disease; DOD, dead of disease; NED, no evidence of disease.
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Figure 3 Urethrocystography showing a vesicovaginal fistula
(arrow) (A, B).
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postoperative complications. In this study, we have re-
ported eight patients with vault failures who underwent
vault resection.
Choi et al. reported four cases of laparoscopic upper
vaginectomy for vaginal intraepithelial neoplasia and
superficially invasive vaginal carcinoma after hysterec-
tomy without radiotherapy [6]. Their operations were
adapted for a recurrent lesion in the upper third of the
vagina, and laparoscopic upper vaginectomy succeeded
in controlling these cases without second vault failure.
Panici et al. reported cases in which vaginectomies
were performed in patients who underwent radical hys-
terectomy without pelvic radiotherapy [7]. In this series,
early postoperative complications were experienced by
seven of the patients who had undergone vaginal vagi-
nectomy: four patients developed vaginal scar abscess
dehiscence, two experienced postoperative bleeding, and
one developed a vesicovaginal fistula. Six subsequent
complications were also observed: three patients devel-
oped vaginal stenosis, two patients developed urinary in-
continence, and one patient developed ureteral stenosis.
After vaginectomy, seven patients developed metastases,
but no patient developed a second vaginal failure. Five-
year overall and progression-free survival rates were 70.5%
and 59.4%, respectively. Panici et al. concluded that vagi-
nal vaginectomy was feasible in selected patients. Their
study’s selection criteria were as follows: patients were in-
cluded if they had vaginal lesions <2 cm in size that were
not juxtaposed to the rectum or bladder, and patients were
excluded if they had prior radiation, prior nodal metasta-
sis, palpable paravaginal invasion, or positive results in ex-
aminations for metastasis (including positron emission
tomography (PET)). The criteria for performing a pre-
operative PET-computed tomography were the absence of
both bulky tumor and distant disease.
In contrast to these previous reports, radiotherapy had
been already performed in our study because of its good
efficacy. At the second vault failure after radiotherapy,resection of the vault was performed via laparotomy.
Total vaginectomy resulted in complications (grade 3,
37.5%; 3/8) because of the adherence of the bladder and
rectum after the first surgery and radiotherapy. Bladder
filling was used to identify the altered anatomy after
prior hysterectomy, as well as the induration of the vagi-
nal vault leading to the bladder, vaginal apex, and
border. Postoperative repeated cystitis and neurogenic
bladder required longer hospitalization. Three patients
developed vesicovaginal fistulae, which are associated
with a high risk of severe complications. Vesicovaginal
fistulae were managed conservatively, and fortunately,
each of the patient’s fistulae closed spontaneously. Tech-
nically feasible procedures could result in maintained
bladder or bowel function.
Conclusions
Although this report is somewhat limited by the small
number of patients, our results suggest that vaginectomy
after radiotherapy is effective. In this series, local control
was achieved in five cases. Since vaginal resection can be
performed to achieve local control, this surgery is an op-
tion for vaginal vault recurrence, as is pelvic exenteration.
However, an earlier study showed higher complication
rates when this operation was performed after hysterec-
tomy and brachytherapy. Because of the associated com-
plications, vaginectomy should only be selected after
carefully considering possible alternatives. For patients
who have been selected carefully, vaginal resection is an
acceptable treatment option.
Because of the rarity of the cases that we have consid-
ered, single-institution studies with large sample are likely
to be infeasible. We suggest that data pooling is the most
promising avenue for identifying optimal therapies and
achieving other progress in this field. Such data pooling
could come in the form of a review of all previously
published case reports, case series, and small studies;
the organization of prospective, multicenter case series;
and/or the referral of all similar cases in Japan to a select
group of medical institutes.
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